Telix Pharmaceuticals’ (TLX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a research note published on Friday,Benzinga reports. They currently have a $20.00 target price on the stock.

A number of other equities research analysts have also weighed in on TLX. Wedbush reiterated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, September 23rd. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, September 21st. Finally, Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $20.50.

Telix Pharmaceuticals Stock Performance

Shares of Telix Pharmaceuticals stock opened at $11.45 on Friday. Telix Pharmaceuticals has a twelve month low of $6.28 and a twelve month high of $13.11. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. The company’s 50 day moving average is $11.35 and its 200 day moving average is $10.50.

Institutional Trading of Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the last quarter. XY Capital Ltd bought a new stake in shares of Telix Pharmaceuticals during the 1st quarter valued at $120,000. Lazard Asset Management LLC increased its stake in shares of Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares in the last quarter. Private Advisor Group LLC increased its stake in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after purchasing an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals in the 2nd quarter worth $1,731,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.